Important update in shingles prevention with SHINGRIX

Posted Tuesday 24 December 2024 | GlaxoSmithKline (GSK)

GlaxoSmithKline (GSK) invites you to attend an upcoming live webinar where Professor Tony Cunningham will provide an overview of shingles and the development of SHINGRIX (Recombinant Varicella Zoster Virus glycoprotein E antigen (AS01b adjuvant vaccine)), with a hot off the press update on new long term follow-up data for shingles prevention.

Learning objectives:

1. discuss the impact of shingles on patients and identify who is at risk
2. evaluate the scientific rationale and innovation behind SHINGRIX, and examine its clinical profile
3. analyse the long term follow-up data for SHINGRIX
4. develop strategies for integrating SHINGRIX into your practice.